Once-Daily Fluticasone Propionate is as Effective as Twice-Daily Treatment in Stable, Mild-to-Moderate Childhood Asthma Ian G.C. Hodges; Thelma A. Netherway Disclosures ...

With its approval, exenatide once weekly has joined exenatide twice daily and liraglutide in the GLP-1 agonist armamentarium available to clinicians. Given their adverse effect profile, as a class ...

Yeztugo showed promising results in clinical trials. One study involving women in Africa reported 100% efficacy, with zero ...

The US Food and Drug Administration (FDA) approved Yeztugo, a long-awaited semi-annual injectable treatment for the prevention of HIV, developed by Gilead Sciences. The approval of Yeztugo marks a ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

FDA Approves Yeztugo as First Twice-Yearly Injectable HIV Prevention Option in the U.S. Clinical Trials Show Near-Perfect ...

The U.S. has just approved a powerful new weapon in the fight against HIV: a twice-a-year prevention shot called Yeztugo. Made by Gilead Sciences, the injectable treatment slashes the risk of HIV ...

In two recent studies, this new shot reportedly nearly eliminated new infections in people at substantial risk of HIV.

The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.… ...

While a vaccine to prevent HIV still is needed, some experts say the shot - a drug called lenacapvir - could be the next best ...

FDA Approves Powerful Twice-Yearly Treatment to Prevent HIV Gilead’s Yeztugo will offer an alternative to treatments such as daily pills and every-other-month injections By Joseph Walker and ...

Why FDA approval of new HIV prevention drug is a big deal The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV.